Third-line therapy for chronic myeloid leukemia: current status and future directions

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion protein, a target for tyrosine kinase inhibitors (TKIs).
• While TKIs have improved CML prognosis, treatment failure due to resistance mutations and adverse effects is common.
• Efficacy diminishes with successive TKI lines, particularly in the third-line (3L) setting.

Purpose of the Study:

• To review the challenges in CML treatment, focusing on TKI resistance and adverse effects.
• To highlight the unmet need for novel therapeutic strategies in the third-line (3L) and beyond settings for CML patients.
• To emphasize the necessity for updated clinical guidelines for managing advanced CML.

Main Methods:

• Literature review of studies on CML pathogenesis, TKI mechanisms, resistance mutations, and treatment outcomes.
• Analysis of clinical data regarding the efficacy and safety of first- and second-generation TKIs in different treatment lines.
• Synthesis of information on emerging therapies and treatment strategies for advanced CML.

Main Results:

• BCR-ABL1 mutations in the ATP binding site confer resistance to approved TKIs.
• Adverse effects of TKIs can lead to treatment discontinuation.
• Limited clinical benefit is observed with third-line (3L) second-generation TKIs (2GTKIs) after prior TKI failures.

Conclusions:

• Current TKI therapies are insufficient for a significant proportion of CML patients, especially in later treatment lines.
• There is a critical need for novel treatment options and clear guidelines for CML patients requiring third-line (3L) therapy and beyond.
• Further research and development of innovative therapies are essential to improve outcomes for CML patients with limited treatment options.